Form 4: Nurix Therapeutics Director, Judith A. Reinsdorf, Reports Stock Option Grant

Judith A. Reinsdorf, a director of Nurix Therapeutics, reported the acquisition of a stock option to purchase 25,000 shares of common stock, vesting fully by May 19, 2026, subject to continued service.

Summary

• On May 19, 2025, Judith A. Reinsdorf, a director of Nurix Therapeutics, Inc. (NRIX), reported the grant of a stock option.
• The stock option allows Reinsdorf to purchase 25,000 shares of Nurix Therapeutics' common stock at an exercise price of $9.51 per share.
• The options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 19, 2026, contingent upon continued service to the Issuer.
• Following the transaction, Reinsdorf directly owns 25,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It's a routine part of corporate governance.

Positives

• The granting of stock options to directors aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term growth.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, especially in the biotech sector.
• The vesting schedule, contingent on continued service, is also typical.
• The size of the grant (25,000 shares) would need to be compared to similar grants at peer companies to assess its relative value.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates

Keywords

stock option, Form 4, director, Nurix Therapeutics, NRIX, insider trading